JP2024170456A5 - - Google Patents

Download PDF

Info

Publication number
JP2024170456A5
JP2024170456A5 JP2024144789A JP2024144789A JP2024170456A5 JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5 JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024144789 A JP2024144789 A JP 2024144789A JP 2024170456 A5 JP2024170456 A5 JP 2024170456A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024144789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024170456A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/058648 external-priority patent/WO2020092427A1/en
Application filed filed Critical
Publication of JP2024170456A publication Critical patent/JP2024170456A/ja
Publication of JP2024170456A5 publication Critical patent/JP2024170456A5/ja
Pending legal-status Critical Current

Links

JP2024144789A 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法 Pending JP2024170456A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP18203183.1 2018-10-29
EP18203183 2018-10-29
US201862752641P 2018-10-30 2018-10-30
US62/752,641 2018-10-30
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS
JP2021524345A JP2022506761A (ja) 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021524345A Division JP2022506761A (ja) 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法

Publications (2)

Publication Number Publication Date
JP2024170456A JP2024170456A (ja) 2024-12-10
JP2024170456A5 true JP2024170456A5 (https=) 2025-07-07

Family

ID=70462698

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524345A Pending JP2022506761A (ja) 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法
JP2024144789A Pending JP2024170456A (ja) 2018-10-29 2024-08-26 IgA抗体構築物を含む組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021524345A Pending JP2022506761A (ja) 2018-10-29 2019-10-29 IgA抗体構築物を含む組成物および方法

Country Status (9)

Country Link
US (1) US20210332131A1 (https=)
EP (1) EP3873942A4 (https=)
JP (2) JP2022506761A (https=)
KR (1) KR20210096612A (https=)
CN (1) CN113260632A (https=)
AU (1) AU2019369397A1 (https=)
CA (1) CA3118312A1 (https=)
GB (1) GB2596411B (https=)
WO (1) WO2020092427A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004979A (ko) * 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022125439A2 (en) * 2020-12-07 2022-06-16 The Regents Of The University Of California Innate immune cell silencing by sirp-alpha engager
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”
WO2023154730A2 (en) * 2022-02-09 2023-08-17 Exelixis, Inc. Multispecific binding agents and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
EP2477648B1 (en) * 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2013087912A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
CN105121467B (zh) * 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US10087257B2 (en) * 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
HUE046661T2 (hu) * 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
NZ741324A (en) * 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
HUE073389T2 (hu) * 2016-09-01 2026-01-28 Tigatx Inc CD20 antitestek
EP3574009A4 (en) * 2017-01-26 2020-11-25 Zlip Holding Limited CD47 ANTIGEN BINDING UNIT AND ITS USES
AU2018308191B2 (en) * 2017-07-24 2023-12-21 Scenic Immunology B.V. Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction
ES2933256T3 (es) * 2017-08-08 2023-02-03 Hoffmann La Roche Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG

Similar Documents

Publication Publication Date Title
JP2024059739A5 (https=)
JP2022068302A5 (https=)
JP2023116721A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2023022224A5 (https=)
JP2021185136A5 (https=)
JP2024016014A5 (https=)
JP2023100643A5 (https=)
JP2022060295A5 (https=)
JP2024112817A5 (https=)
JP2025084837A5 (https=)
JP2024063214A5 (https=)
JP2020120660A5 (https=)
JP2023085551A5 (https=)
JP2023011759A5 (https=)
JP2024170456A5 (https=)
JP2025066722A5 (https=)
JP2022022379A5 (https=)
JP2022122912A5 (https=)
JP2020141705A5 (https=)
JP2022172276A5 (https=)
JP2023153118A5 (https=)
JPWO2021132577A5 (https=)
JP2023097358A5 (https=)